Linked Life Data

12439851

Source:http://linkedlifedata.com/resource/pubmed/id/12439851

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2002-11-19
pubmed:abstractText
In a strategy termed "Protease Targeting", retroviral vectors carrying an EGF infectivity-blocking domain fused to the N-terminus of the envelope SU via a MMP (matrix metalloproteinase)-cleavable linker were successfully used to target gene delivery to EGF receptor-(EGF-R-)positive tumour cells over-expressing MMPs. In the current study, we aimed to investigate whether this strategy could be applied to (a) limit the cytotoxic activity of a hyperfusogenic GALV therapeutic gene, and (b) enhance the immune-stimulatory properties of GALV via local, MMP-mediated release human granulocyte-macrophage colony stimulating factor (GM-CSF).
pubmed:language
eng
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:author
pubmed:copyrightInfo
Copyright 2002 John Wiley & Sons, Ltd.
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
592-600
pubmed:dateRevised
2006-11-15
pubmed:articleTitle
Lack of specificity of cell-surface protease targeting of a cytotoxic hyperfusogenic gibbon ape leukaemia virus envelope glycoprotein.
pubmed:affiliation
Molecular Medicine Program, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.